Epidemiology of venous thromboembolism

Nature Reviews Cardiology

Volumn 12, Issue 8, 2015, Pages 464-474

  Heit, John A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFRICAN AMERICAN; AMERICAN INDIAN; ASIAN AMERICAN; CAUCASIAN; HEALTH CARE COST; HOSPITALIZATION; HUMAN; INCIDENCE; PREDICTION; PRIORITY JOURNAL; PROPHYLAXIS; RECURRENT DISEASE; REVIEW; RISK FACTOR; SURVIVAL; VENOUS THROMBOEMBOLISM; ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; CHILD; COST; ECONOMICS; EPIDEMIOLOGY; FEMALE; INFANT; LEG; MALE; MIDDLE AGED; MORTALITY; NEWBORN; PELVIS; PRESCHOOL CHILD; PULMONARY EMBOLISM; SECONDARY PREVENTION; VASCULARIZATION; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; COSTS AND COST ANALYSIS; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; LEG; MALE; MIDDLE AGED; PELVIS; PULMONARY EMBOLISM; RECURRENCE; SECONDARY PREVENTION; VENOUS THROMBOEMBOLISM; YOUNG ADULT;

EID: 84938198885     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2015.83     Document Type: Review

References (271)

1. Souto, J. C., et al. Genetic susceptibility to thrombosis and its relationship to physiological risk factors: the GAIT study. Genetic Analysis of Idiopathic Thrombophilia. Am. J. Hum. Genet. 67, 1452-1459 (2000
2. Ariëns, R. A., et al. Activation markers of coagulation and fibrinolysis in twins: heritability of the prethrombotic state. Lancet 359, 667-671 (2002
3. Larsen, T. B., et al. Major genetic susceptibility for venous thromboembolism in men: a study of Danish twins. Epidemiology 14, 328-332 (2003
4. Heit, J. A., et al. Familial segregation of venous thromboembolism. J. Thromb. Haemost. 2, 731-736 (2004
5. Zöller, B., Ohlsson, H., Sundquist, J., & Sundquist, K. Familial risk of venous thromboembolism in first , second-And third-degree relatives: a nationwide family study in Sweden. Thromb. Haemost. 109, 458-463 (2013
6. Zöller, B., Li, X., Sundquist, J., & Sundquist, K. A nationwide family study of pulmonary embolism: identification of high risk families with increased risk of hospitalized and fatal pulmonary embolism. Thromb. Res. 130, 178-182 (2012
7. Zöller, B., Li, X., Sundquist, J., & Sundquist, K. Shared familial aggregation of susceptibility to different manifestations of venous thromboembolism: a nationwide family study in Sweden. Br. J. Haematol. 157, 146-148 (2012
8. Anderson, F. A. Jr, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch. Intern. Med. 151, 933-938 (1991
9. Hansson, P. O., Welin, L., Tibblin, G., & Eriksson, H. Deep vein thrombosis and pulmonary embolism in the general population. 'The Study of Men Born in 1913'. Arch. Intern. Med. 157, 1665-1670 (1997
10. Silverstein, M. D., et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch. Intern. Med. 158, 585-593 (1998
11. Oger, E. Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP Study Group. Groupe d'Etude de la Thrombose de Bretagne Occidentale. Thromb. Haemost. 83, 657-660 (2000
12. Cushman, M., et al. Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology. Am. J. Med. 117, 19-25 (2004
13. Heit, J. A. Venous thromboembolism: disease burden, outcomes and risk factors. J. Thromb. Haemost. 3, 1611-1617 (2005
14. Spencer, F. A., et al. The Worcester Venous Thromboembolism study: a population-based study of the clinical epidemiology of venous thromboembolism. J. Gen. Intern. Med. 21, 722-727 (2006
15. Naess, I. A., et al. Incidence and mortality of venous thrombosis: a population-based study. J. Thromb. Haemost. 5, 692-699 (2007
16. Spencer, F. A., et al. Incidence rates, clinical profile, and outcomes of patients with venous thromboembolism. The Worcester VTE study. J. Thromb. Thrombolysis 28, 401-409 (2009
17. Tagalakis, V., Patenaude, V., Kahn, S. R., & Suissa, S. Incidence of and mortality from venous thromboembolism in a real-world population: the Q VTE Study Cohort. Am. J. Med. 126, 832.e13-832.e21 (2013
18. Huang, W., Goldberg, R. J., Anderson, F. A., Kiefe, C. I., & Spencer, F. A. Secular trends in occurrence of acute venous thromboembolism: the Worcester VTE study (1985-2009). Am. J. Med. 127, 829-839.e5 (2014
19. Rothwell, P. M., et al. Change in stroke incidence, mortality, case-fatality, severity, and risk factors in Oxfordshire, UK from 1981 to 2004 (Oxford Vascular Study). Lancet 363, 1925-1933 (2004
20. Koton, S., et al. Stroke incidence and mortality trends in US communities, 1987 to 2011. JAMA 312, 259-268 (2014
21. White, R. H., Zhou, H., & Romano, P. S. Incidence of idiopathic deep venous thrombosis and secondary thromboembolism among ethnic groups in California. Ann. Intern. Med. 128, 737-740 (1998
22. Schneider, D., Lilienfeld, D. E., & Im, W. The epidemiology of pulmonary embolism: racial contrasts in incidence and in-hospital case fatality. J. Natl Med. Assoc. 98, 1967-1972 (2006
23. Zakai, N. A., et al. Racial and regional differences in venous thromboembolism in the United States in 3 cohorts. Circulation 129, 1502-1509 (2014
24. Cheuk, B. L., Cheung, G. C., & Cheng, S. W. Epidemiology of venous thromboembolism in a Chinese population. Br. J. Surg. 91, 424-428 (2004
25. Klatsky, A. L., Armstrong, M. A., & Poggi, J. Risk of pulmonary embolism and/or deep venous thrombosis in Asian-Americans. Am. J. Cardiol. 85, 1334-1337 (2000
26. White, R. H., Zhou, H., Murin, S., & Harvey, D. Effect of ethnicity and gender on the incidence of venous thromboembolism in a diverse population in California in 1996. Thromb. Haemost. 93, 298-305 (2005
27. Hooper, W. C., Holman, R. C., Heit, J. A., & Cobb, N. Venous thromboembolism hospitalizations among American Indians and Alaska Natives. Thromb. Res. 108, 273-278 (2002
28. Heit, J. A., et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch. Intern. Med. 162, 1245-1248 (2002
29. Heit, J. A., Sobell, J. L., Li, H., & Sommer, S. S. The incidence of venous thromboembolism among Factor V Leiden carriers: a community-based cohort study. J. Thromb. Haemost. 3, 305-311 (2005
30. Prandoni, P., et al. The long-Term clinical course of acute deep venous thrombosis. Ann. Intern. Med. 125, 1-7 (1996
31. Heit, J. A., et al. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch. Intern. Med. 160, 761-768 (2000
32. Hansson, P. O., Sörbo, J., & Eriksson, H. Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. Arch. Intern. Med. 160, 769-774 (2000
33. van Dongen, C. J., Vink, R., Hutten, B. A., Büller, H. R., & Prins, M. H. The incidence of recurrent venous thromboembolism after treatment with vitamin K antagonists in relation to time since first event: a meta-Analysis. Arch. Intern. Med. 163, 1285-1293 (2003
34. Schulman, S., et al. Post-Thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months. J. Thromb. Haemost. 4, 734-742 (2006
35. Prandoni, P., et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1, 626 patients. Haematologica 92, 199-205 (2007
36. Spencer, F. A., et al. Patient outcomes after deep vein thrombosis and pulmonary embolism: the Worcester Venous Thromboembolism Study. Arch. Intern. Med. 168, 425-430 (2008
37. Nieto, J. A., et al. Clinical outcome of patients with major bleeding after venous thromboembolism. Findings from the RIETE Registry. Thromb. Haemost. 100, 789-796 (2008
38. White, R. H., Chan, W. S., Zhou, H., & Ginsberg, J. S. Recurrent venous thromboembolism after pregnancy-Associated versus unprovoked thromboembolism. Thromb. Haemost. 100, 246-252 (2008
39. Kyrle, P. A., Rosendaal, F. R., & Eichinger, S. Risk assessment for recurrent venous thrombosis. Lancet 376, 2032-2039 (2010
40. Verso, M., et al. Long-Term death and recurrence in patients with acute venous thromboembolism: the MASTER registry. Thromb. Res. 130, 369-373 (2012
41. Schulman, S., et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group. N. Engl. J. Med. 336, 393-398 (1997
42. Kearon, C., et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N. Engl. J. Med. 340, 901-907 (1999
43. Agnelli, G., et al. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators. N. Engl. J. Med. 345, 165-169 (2001
44. Schulman, S., et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group. N. Engl. J. Med. 332, 1661-1665 (1995
45. Agnelli, G., et al. Extended oral anticoagulant therapy after a first episode of pulmonary embolism. Ann. Intern. Med. 139, 19-25 (2003
46. Prandoni, P., et al. Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism. Ann. Intern. Med. 137, 955-960 (2002
47. Kyrle, P. A., & Eichinger, S. The risk of recurrent venous thromboembolism: the Austrian Study on Recurrent Venous Thromboembolism. Wien. Klin. Wochenschr. 115, 471-474 (2003
48. Douketis, J. D., Foster, G. A., Crowther, M. A., Prins, M. H., & Ginsberg, J. S. Clinical risk factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapy. Arch. Intern. Med. 160, 3431-3436 (2000
49. Murin, S., Romano, P. S., & White, R. H. Comparison of outcomes after hospitalization for deep venous thrombosis or pulmonary embolism. Thromb. Haemost. 88, 407-414 (2002
50. Kyrle, P. A., et al. The risk of recurrent venous thromboembolism in men and women. N. Engl. J. Med. 350, 2558-2563 (2004
51. Laczkovics, C., et al. Risk of recurrence after a first venous thromboembolic event in young women. Haematologica 92, 1201-1207 (2007
52. Kim, T. M., et al. Clinical predictors of recurrent venous thromboembolism: a single institute experience in Korea. Thromb. Res. 123, 436-443 (2009
53. Eichinger, S., et al. Overweight, obesity, and the risk of recurrent venous thromboembolism. Arch. Intern. Med. 168, 1678-1683 (2008
54. Romualdi, E., Squizzato, A., & Ageno, W. Abdominal obesity and the risk of recurrent deep vein thrombosis. Thromb. Res. 119, 687-690 (2007
55. Garcia-Fuster, M. J., et al. Long-Term prospective study of recurrent venous thromboembolism in patients younger than 50 years. Pathophysiol. Haemost. Thromb. 34, 6-12 (2005
56. Heit, J. A., et al. Genetic variation within the anticoagulant, procoagulant, fibrinolytic and innate immunity pathways as risk factors for venous thromboembolism. J. Thromb. Haemost. 9, 1133-1142 (2011
57. Agnelli, G., Becattini, C., & Prandoni, P. Recurrent venous thromboembolism in men and women. N. Engl. J. Med. 351, 2015-2018 (2004
58. Baglin, T., Luddington, R., Brown, K., & Baglin, C. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet 362, 523-526 (2003
59. Baglin, T., Luddington, R., Brown, K., & Baglin, C. High risk of recurrent venous thromboembolism in men. J. Thromb. Haemost. 2, 2152-2155 (2004
60. McRae, S., Tran, H., Schulman, S., Ginsberg, J., & Kearon, C. Effect of patient's sex on risk of recurrent venous thromboembolism: a meta-Analysis. Lancet 368, 371-378 (2006
61. Lijfering, W. M., et al. A lower risk of recurrent venous thrombosis in women compared with men is explained by sex-specific risk factors at time of first venous thrombosis in thrombophilic families. Blood 114, 2031-2036 (2009
62. Le Gal, G., et al. Risk of recurrent venous thromboembolism after a first oestrogen-Associated episode. Data from the REVERSE cohort study. Thromb. Haemost. 104, 498-503 (2010
63. Christiansen, S. C., Lijfering, W. M., Helmerhorst, F. M., Rosendaal, F. R., & Cannegieter, S. C. Sex difference in risk of recurrent venous thrombosis and the risk profile for a second event. J. Thromb. Haemost. 8, 2159-2168 (2010
64. Douketis, J., et al. Risk of recurrence after venous thromboembolism in men and women: patient level meta-Analysis. BMJ 342, d813 (2011
65. Hutten, B. A., et al. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J. Clin. Oncol. 18, 3078-3083 (2000
66. Pinede, L., et al. Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis. Circulation 103, 2453-2460 (2001
67. Prandoni, P., et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 100, 3484-3488 (2002
68. Louzada, M. L., Majeed, H., Dao, V., & Wells, P. S. Risk of recurrent venous thromboembolism according to malignancy characteristics in patients with cancer-Associated thrombosis: a systematic review of observational and intervention studies. Blood Coagul. Fibrinolysis 22, 86-91 (2011
69. Louzada, M. L., et al. Development of a clinical prediction rule for risk stratification of recurrent venous thromboembolism in patients with cancer-Associated venous thromboembolism. Circulation 126, 448-454 (2012
70. Chee, C. E., et al. Predictors of venous thromboembolism recurrence and bleeding among active cancer patients: a population-based cohort study. Blood 123, 3972-3978 (2014
71. Iorio, A., et al. Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review. Arch. Intern. Med. 170, 1710-1716 (2010
72. Baglin, T., et al. Does the clinical presentation and extent of venous thrombosis predict likelihood and type of recurrence?. A patient-level meta-Analysis. J. Thromb. Haemost. 8, 2436-2442 (2010
73. Kovacs, M. J., et al. Patients with a first symptomatic unprovoked deep vein thrombosis are at higher risk of recurrent venous thromboembolism than patients with a first unprovoked pulmonary embolism. J. Thromb. Haemost. 8, 1926-1932 (2010
74. Schulman, S., Svenungsson, E., & Granqvist, S. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group. Am. J. Med. 104, 332-338 (1998
75. Garcia, D., Akl, E. A., Carr, R., & Kearon, C. Antiphospholipid antibodies and the risk of recurrence after a first episode of venous thromboembolism: a systematic review. Blood 122, 817-824 (2013
76. Jayakody Arachchillage, D., & Greaves, M. The chequered history of the antiphospholipid syndrome. Br. J. Haematol. 165, 609-617 (2014
77. van den Belt, A. G., et al. Recurrence of venous thromboembolism in patients with familial thrombophilia. Arch. Intern. Med. 157, 2227-2232 (1997
78. Vossen, C. Y., et al. Risk of a first venous thrombotic event in carriers of a familial thrombophilic defect. The European Prospective Cohort on Thrombophilia (EPCOT). J. Thromb. Haemost. 3, 459-464 (2005
79. Brouwer, J. L., et al. High long-Term absolute risk of recurrent venous thromboembolism in patients with hereditary deficiencies of protein S, protein C or antithrombin. Thromb. Haemost. 101, 93-99 (2009
80. den Heijer, M., et al. Homocysteine lowering by B vitamins and the secondary prevention of deep vein thrombosis and pulmonary embolism: a randomized, placebo-controlled, double-blind trial. Blood 109, 139-144 (2007
81. Verhovsek, M., et al. Systematic review: D dimer to predict recurrent disease after stopping anticoagulant therapy for unprovoked venous thromboembolism. Ann. Intern. Med. 149, 481-490 (2008
82. Douketis, J., et al. Patient-level meta-Analysis: effect of measurement timing, threshold, and patient age on ability of D dimer testing to assess recurrence risk after unprovoked venous thromboembolism. Ann. Intern. Med. 153, 523-531 (2010
83. Cosmi, B., et al. Usefulness of repeated D dimer testing after stopping anticoagulation for a first episode of unprovoked venous thromboembolism: the PROLONG II prospective study. Blood 115, 481-488 (2010
84. Palareti, G., et al. D dimer to guide the duration of anticoagulation in patients with venous thromboembolism: a management study. Blood 124, 196-203 (2014
85. Tan, M., Mos, I. C., Klok, F. A., & Huisman, M. V. Residual venous thrombosis as predictive factor for recurrent venous thromboembolim in patients with proximal deep vein thrombosis: a sytematic review. Br. J. Haematol. 153, 168-178 (2011
86. Le Gal, G., et al. Residual vein obstruction as a predictor for recurrent thromboembolic events after a first unprovoked episode: data from the REVERSE cohort study. J. Thromb. Haemost. 9, 1126-1132 (2011
87. Ho, W. K., Hankey, G. J., Quinlan, D. J., & Eikelboom, J. W. Risk of recurrent venous thromboembolism in patients with common thrombophilia: a systematic review. Arch. Intern. Med. 166, 729-736 (2006
88. Gándara, E., et al. Non-OO blood type influences the risk of recurrent venous thromboembolism. A cohort study. Thromb. Haemost. 110, 1172-1179 (2013
89. Zhu, T., Martinez, I., & Emmerich, J. Venous thromboembolism: risk factors for recurrence. Arterioscler. Thromb. Vasc. Biol. 29, 298-310 (2009
90. Cushman, M., et al. Hormonal factors and risk of recurrent venous thrombosis: the prevention of recurrent venous thromboembolism trial. J. Thromb. Haemost. 4, 2199-2203 (2006
91. Biere-Rafi, S., et al. Statin treatment and the risk of recurrent pulmonary embolism. Eur. Heart J. 34, 1800-1806 (2013
92. White, R. H., Murin, S., Wun, T., & Danielsen, B. Recurrent venous thromboembolism after surgery-provoked versus unprovoked thromboembolism. J. Thromb. Haemost. 8, 987-997 (2010
93. Douketis, J. D., Crowther, M. A., Foster, G. A., & Ginsberg, J. S. Does the location of thrombosis determine the risk of disease recurrence in patients with proximal deep vein thrombosis?. Am. J. Med. 110, 515-519 (2001
94. Eichinger, S., et al. Symptomatic pulmonary embolism and the risk of recurrent venous thromboembolism. Arch. Intern. Med. 164, 92-96 (2004
95. Jiménez, D., et al. The risk of recurrent venous thromboembolism in patients with unprovoked symptomatic deep vein thrombosis and asymptomatic pulmonary embolism. Thromb. Haemost. 95, 562-566 (2006
96. Boutitie, F., et al. Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants' data from seven trials. BMJ 342, d3036 (2011
97. Galanaud, J. P., et al. Incidence and predictors of venous thromboembolism recurrence after a first isolated distal deep vein thrombosis. J. Thromb. Haemost. 12, 436-443 (2014
98. den Exter, P. L., et al. Risk profile and clinical outcome of symptomatic subsegmental acute pulmonary embolism. Blood 122, 1144-1149 (2013
99. Rodger, M. A., et al. Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ 179, 417-426 (2008
100. Eichinger, S., Heinze, G., Jandeck, L. M., & Kyrle, P. A. Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model. Circulation 121, 1630-1636 (2010
101. Tosetto, A., et al. Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH). J. Thromb. Haemost. 10, 1019-1025 (2012
102. Kyrle, P. A., & Eichinger, S. Clinical scores to predict recurrence risk of venous thromboembolism. Thromb. Haemost. 108, 1061-1064 (2012
103. Poli, D., & Palareti, G. Assessing recurrence risk following acute venous thromboembolism: use of algorithms. Curr. Opin. Pulm. Med. 19, 407-412 (2013
104. den Exter, P. L., Kooiman, J., & Huisman, M. V. Validation of the Ottawa prognostic score for the prediction of recurrent venous thromboembolism in patients with cancer-Associated thrombosis. J. Thromb. Haemost. 11, 998-1000 (2013
105. Heit, J. A. Estimating the incidence of symptomatic postoperative venous thromboembolism: the importance of perspective. JAMA 307, 306-307 (2012
106. Cohen, A. T., et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb. Haemost. 98, 756-764 (2007
107. Centers for Disease Control and Prevention (CDC). Venous thromboembolism in adult hospitalizations-United States, 2007-2009. MMWR Morb. Mortal. Wkly Rep. 61, 401-404 (2012
108. Cohoon, K. P., et al. Costs of venous thromboembolism associated with hospitalization for medical illness. Am. J. Manag. Care 21, e255-e263 (2015
109. Cohoon, K. P., et al. Direct medical costs attributable to venous thromboembolism among persons hospitalized for major surgery: a population-based longitudinal study. Surgery 157, 423-431 (2015
110. ISTH Steering Committee for World Thrombosis Day. Thrombosis: a major contributor to the global disease burden. J. Thromb. Haemost. 12, 1580-1590 (2014
111. Heit, J. A., et al. Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort study. Arch. Intern. Med. 159, 445-453 (1999
112. Goldhaber, S. Z., Visani, L., & De Rosa, M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet 353, 1386-1389 (1999
113. Janata, K., et al. Mortality of patients with pulmonary embolism. Wien. Klin. Wochenschr. 114, 766-772 (2002
114. Andresen, M. S., et al. Mortality and recurrence after treatment of VTE: long term follow-up of patients with good life-expectancy. Thromb. Res. 127, 540-546 (2011
115. Søgaard, K. K., Schmidt, M., Pedersen, L., Horváth-Puhó, E., & Sørensen, H. T. 30-year mortality after venous thromboembolism: a population-based cohort study. Circulation 130, 829-836 (2014
116. Agnelli, G., & Becattini, C. Acute pulmonary embolism. N. Engl. J. Med. 363, 266-274 (2010
117. Konstantinides, S., et al. Association between thrombolytic treatment and the prognosis of hemodynamically stable patients with major pulmonary embolism: results of a multicenter registry. Circulation 96, 882-888 (1997
118. Horlander, K. T., Mannino, D. M., & Leeper, K. V. Pulmonary embolism mortality in the United States, 1979-1998: an analysis using multiple-cause mortality data. Arch. Intern. Med. 163, 1711-1717 (2003
119. Tsai, J., Grosse, S. D., Grant, A. M., Hooper, W. C., & Atrash, H. K. Trends in in-hospital deaths among hospitalizations with pulmonary embolism. Arch. Intern. Med. 172, 960-961 (2012
120. Barsoum, M. K., et al. Is progestin an independent risk factor for incident venous thromboembolism?. A population-based case-control study. Thromb. Res. 126, 373-378 (2010
121. Heit, J. A., et al. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch. Intern. Med. 160, 809-815 (2000
122. Cushman, M., et al. Fibrin fragment D dimer and the risk of future venous thrombosis. Blood 101, 1243-1248 (2003
123. Smeeth, L., et al. Risk of deep vein thrombosis and pulmonary embolism after acute infection in a community setting. Lancet 367, 1075-1079 (2006
124. Sweetland, S., et al. Duration and magnitude of the postoperative risk of venous thromboembolism in middle aged women: prospective cohort study. BMJ 339, b4583 (2009
125. Bezemer, I. D., van der Meer, F. J., Eikenboom, J. C., Rosendaal, F. R., & Doggen, C. J. The value of family history as a risk indicator for venous thrombosis. Arch. Intern. Med. 169, 610-615 (2009
126. Roach, R. E., Lijfering, W. M., Flinterman, L. E., Rosendaal, F. R., & Cannegieter, S. C. Increased risk of CVD after VT is determined by common etiologic factors. Blood 121, 4948-4954 (2013
127. Cannegieter, S. C., et al. Risk of venous and arterial thrombotic events in patients diagnosed with superficial vein thrombosis: a nationwide cohort study. Blood 125, 229-235 (2015
128. Heit, J. A., et al. Incidence of venous thromboembolism in hospitalized patients vs community residents. Mayo Clin. Proc. 76, 1102-1110 (2001
129. Noboa, S., Mottier, D., Oger, E., & EPI-GETBO Study Group. Estimation of a potentially preventable fraction of venous thromboembolism: a community-based prospective study. J. Thromb. Haemost. 4, 2720-2722 (2006
130. Samama, M. M. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Arch. Intern. Med. 160, 3415-3420 (2000
131. Geerts, W. H., et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133, 381S-453S (2008
132. Sweetland, S., et al. Smoking, surgery, and venous thromboembolism risk in women: United Kingdom cohort study. Circulation 127, 1276-1282 (2013
133. White, R. H., Zhou, H., & Romano, P. S. Incidence of symptomatic venous thromboembolism after different elective or urgent surgical procedures. Thromb. Haemost. 90, 446-455 (2003
134. Edmonds, M. J., Crichton, T. J., Runciman, W. B., & Pradhan, M. Evidence-based risk factors for postoperative deep vein thrombosis. ANZ J. Surg. 74, 1082-1097 (2004
135. Goldhaber, S. Z., Tapson, V. F., & DVT FREE Steering Committee. A prospective registry of 5, 451 patients with ultrasound-confirmed deep vein thrombosis. Am. J. Cardiol. 93, 259-262 (2004
136. Anderson, F. A. Jr, Hirsh, J., White, K., Fitzgerald, R. H. Jr & Hip and Knee Registry Investigators. Temporal trends in prevention of venous thromboembolism following primary total hip or knee arthroplasty 1996-2001: findings from the Hip and Knee Registry. Chest 124 (Suppl. 6), 349S-356S (2003
137. White, R. H., Gettner, S., Newman, J. M., Trauner, K. B., & Romano, P. S. Predictors of rehospitalization for symptomatic venous thromboembolism after total hip arthroplasty. N. Engl. J. Med. 343, 1758-1764 (2000
138. Parkin, L., et al. Body mass index, surgery, and risk of venous thromboembolism in middle-Aged women: a cohort study. Circulation 125, 1897-1904 (2012
139. Mantilla, C. B., Horlocker, T. T., Schroeder, D. R., Berry, D. J., & Brown, D. L. Risk factors for clinically relevant pulmonary embolism and deep venous thrombosis in patients undergoing primary hip or knee arthroplasty. Anesthesiology 99, 552-560 (2003
140. Zakai, N. A., Wright, J., & Cushman, M. Risk factors for venous thrombosis in medical inpatients: validation of a thrombosis risk score. J. Thromb. Haemost. 2, 2156-2161 (2004
141. Chopard, P., Spirk, D., & Bounameaux, H. Identifying acutely ill medical patients requiring thromboprophylaxis. J. Thromb. Haemost. 4, 915-916 (2006
142. Barbar, S., et al. A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score. J. Thromb. Haemost. 8, 2450-2457 (2010
143. Rothberg, M. B., Lindenauer, P. K., Lahti, M., Pekow, P. S., & Selker, H. P. Risk factor model to predict venous thromboembolism in hospitalized medical patients. J. Hosp. Med. 6, 202-209 (2011
144. Spyropoulos, A. C., et al. Predictive and associative models to identify hospitalized medical patients at risk for VTE. Chest 140, 706-714 (2011
145. Woller, S. C., et al. Derivation and validation of a simple model to identify venous thromboembolism risk in medical patients. Am. J. Med. 124, 947-954.e2 (2011
146. Zakai, N. A., Callas, P. W., Repp, A. B., & Cushman, M. Venous thrombosis risk assessment in medical inpatients: the medical inpatients and thrombosis (MITH) study. J. Thromb. Haemost. 11, 634-641 (2013
147. Samama, M. M., Combe, S., Conard, J., & Horellou, M. H. Risk assessment models for thromboprophylaxis of medical patients. Thromb. Res. 129, 127-132 (2012
148. Rothberg, M. B. Venous thromboembolism prophylaxis for medical patients: who needs it?. JAMA Intern. Med. 174, 1585-1586 (2014
149. Chew, H. K., Wun, T., Harvey, D., Zhou, H., & White, R. H. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch. Intern. Med. 166, 458-464 (2006
150. Blom, J. W., et al. Incidence of venous thrombosis in a large cohort of 66, 329 cancer patients: results of a record linkage study. J. Thromb. Haemost. 4, 529-535 (2006
151. Kucuk, O., Kwaan, H. C., Gunnar, W., & Vazquez, R. M. Thromboembolic complications associated with L asparaginase therapy. Etiologic role of low antithrombin III and plasminogen levels and therapeutic correction by fresh frozen plasma. Cancer 55, 702-706 (1985
152. Liebman, H. A., Wada, J. K., Patch, M. J., & McGehee, W. Depression of functional and antigenic plasma antithrombin III (AT-III) due to therapy with L asparaginase. Cancer 50, 451-456 (1982
153. Zangari, M., et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 98, 1614-1615 (2001
154. Knight, R., DeLap, R. J., & Zeldis, J. B. Lenalidomide and venous thrombosis in multiple myeloma. N. Engl. J. Med. 354, 2079-2080 (2006
155. Meier, C. R., & Jick, H. Tamoxifen and risk of idiopathic venous thromboembolism. Br. J. Clin. Pharmacol. 45, 608-612 (1998
156. Baron, J. A., Gridley, G., Weiderpass, E., Nyrén, O., & Linet, M. Venous thromboembolism and cancer. Lancet 351, 1077-1080 (1998
157. Piccioli, A., et al. Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial. J. Thromb. Haemost. 2, 884-889 (2004
158. Tafur, A. J., et al. The association of active cancer with venous thromboembolism location: a population-based study. Mayo Clin. Proc. 86, 25-30 (2011
159. Carrier, M., et al. Systematic review: the Trousseau syndrome revisited: should we screen extensively for cancer in patients with venous thromboembolism?. Ann. Intern. Med. 149, 323-333 (2008
160. Khorana, A. A., Kuderer, N. M., Culakova, E., Lyman, G. H., & Francis, C. W. Development and validation of a predictive model for chemotherapy-Associated thrombosis. Blood 111, 4902-4907 (2008
161. Ay, C., et al. Prediction of venous thromboembolism in cancer patients. Blood 116, 5377-5382 (2010
162. Merrer, J., et al. Complications of femoral and subclavian venous catheterization in critically ill patients: a randomized controlled trial. JAMA 286, 700-707 (2001
163. Decousus, H., et al. Superficial venous thrombosis and venous thromboembolism: a large, prospective epidemiologic study. Ann. Intern. Med. 152, 218-224 (2010
164. Goldhaber, S. Z., et al. Risk factors for pulmonary embolism. The Framingham Study. Am. J. Med. 74, 1023-1028 (1983
165. Cogo, A., et al. Acquired risk factors for deep-vein thrombosis in symptomatic outpatients. Arch. Intern. Med. 154, 164-168 (1994
166. Dalen, J. E. Economy class syndrome: too much flying or too much sitting?. Arch. Intern. Med. 163, 2674-2676 (2003
167. Kuipers, S., et al. The absolute risk of venous thrombosis after air travel: a cohort study of 8, 755 employees of international organisations. PLoS Med. 4, e290 (2007
168. Chandra, D., Parisini, E., & Mozaffarian, D. Meta analysis: travel and risk for venous thromboembolism. Ann. Intern. Med. 151, 180-190 (2009
169. Watson, H. G., & Baglin, T. P. Guidelines on travel-related venous thrombosis. Br. J. Haematol. 152, 31-34 (2011
170. Ray, J. G., et al. Use of statins and the subsequent development of deep vein thrombosis. Arch. Intern. Med. 161, 1405-1410 (2001
171. Lacut, K., et al. Statins but not fibrates are associated with a reduced risk of venous thromboembolism: a hospital-based case-control study. Fundam. Clin. Pharmacol. 18, 477-482 (2004
172. Glynn, R. J., et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N. Engl. J. Med. 360, 1851-1861 (2009
173. Doggen, C. J., et al. Serum lipid levels and the risk of venous thrombosis. Arterioscler. Thromb. Vasc. Biol. 24, 1970-1975 (2004
174. Prandoni, P., et al. An association between atherosclerosis and venous thrombosis. N. Engl. J. Med. 348, 1435-1441 (2003
175. Marcucci, R., et al. Increased plasma levels of lipoprotein(a) and the risk of idiopathic and recurrent venous thromboembolism. Am. J. Med. 115, 601-605 (2003
176. Tsai, A. W., et al. Cardiovascular risk factors and venous thromboembolism incidence: the longitudinal investigation of thromboembolism etiology. Arch. Intern. Med. 162, 1182-1189 (2002
177. Sørensen, H. T., Horvath-Puho, E., Pedersen, L., Baron, J. A., & Prandoni, P. Venous thromboembolism and subsequent hospitalisation due to acute arterial cardiovascular events: a 20-year cohort study. Lancet 370, 1773-1779 (2007
178. Zöller, B., Li, X., Sundquist, J., & Sundquist, K. Venous thromboembolism does not share strong familial susceptibility with coronary heart disease: a nationwide family study in Sweden. Eur. Heart J. 32, 2800-2805 (2011
179. Barsoum, M. K., et al. Are myocardial infarction and venous thromboembolism associated?. Population-based case-control and cohort studies. Thromb. Res. 134, 593-598 (2014
180. Folsom, A. R., & Chamberlain, A. Lipoprotein(a) and venous thromboembolism. Am. J. Med. 121, e17 (2008
181. Chamberlain, A. M., Folsom, A. R., Heckbert, S. R., Rosamond, W. D., & Cushman, M. High-density lipoprotein cholesterol and venous thromboembolism in the Longitudinal Investigation of Thromboembolism Etiology (LITE). Blood 112, 2675-2680 (2008
182. Chasan-Taber, L., & Stampfer, M. J. Epidemiology of oral contraceptives and cardiovascular disease. Ann. Intern. Med. 128, 467-477 (1998
183. Rosendaal, F. R. Risk factors for venous thrombotic disease. Thromb. Haemost. 82, 610-619 (1999
184. Gomes, M. P., & Deitcher, S. R. Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy: a clinical review. Arch. Intern. Med. 164, 1965-1976 (2004
185. Grady, D., et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study. Ann. Intern. Med. 132, 689-696 (2000
186. Grady, D., Hulley, S. B., & Furberg, C. Venous thromboembolic events associated with hormone replacement therapy. JAMA 278, 477 (1997
187. Heit, J. A., et al. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann. Intern. Med. 143, 697-706 (2005
188. Adomaityte, J., Farooq, M., & Qayyum, R. Effect of raloxifene therapy on venous thromboembolism in postmenopausal women. A meta-Analysis. Thromb. Haemost. 99, 338-342 (2008
189. van Hylckama Vlieg, A., Helmerhorst, F. M., & Rosendaal, F. R. The risk of deep venous thrombosis associated with injectable depot-medroxyprogesterone acetate contraceptives or a levonorgestrel intrauterine device. Arterioscler. Thromb. Vasc. Biol. 30, 2297-2300 (2010
190. Smith, N. L., et al. Esterified estrogens and conjugated equine estrogens and the risk of venous thrombosis. JAMA 292, 1581-1587 (2004
191. James, A. H. Venous thromboembolism in pregnancy. Arterioscler. Thromb. Vasc. Biol. 29, 326-331 (2009
192. Danilenko-Dixon, D. R., et al. Risk factors for deep vein thrombosis and pulmonary embolism during pregnancy or post partum: a population-based, case-control study. Am. J. Obstet. Gynecol. 184, 104-110 (2001
193. Roach, R. E., et al. The risk of venous thrombosis in individuals with a history of superficial vein thrombosis and acquired venous thrombotic risk factors. Blood 122, 4264-4269 (2013
194. Sultan, A. A., et al. Risk factors for first venous thromboembolism around pregnancy: a population-based cohort study from the United Kingdom. Blood 121, 3953-3961 (2013
195. Ludvigsson, J. F., Welander, A., Lassila, R., Ekbom, A., & Montgomery, S. M. Risk of thromboembolism in 14, 000 individuals with coeliac disease. Br. J. Haematol. 139, 121-127 (2007
196. Shantsila, E., Lip, G. Y., & Chong, B. H. Heparin induced thrombocytopenia. A contemporary clinical approach to diagnosis and management. Chest 135, 1651-1664 (2009
197. Tsai, A. W., et al. Serum homocysteine, thermolabile variant of methylene tetrahydrofolate reductase (MTHFR), and venous thromboembolism: Longitudinal Investigation of Thromboembolism Etiology (LITE). Am. J. Hematol. 72, 192-200 (2003
198. den Heijer, M., Lewington, S., & Clarke, R. Homocysteine, MTHFR and risk of venous thrombosis: a meta-Analysis of published epidemiological studies. J. Thromb. Haemost. 3, 292-299 (2005
199. van Zaane, B., et al. Increasing levels of free thyroxine as a risk factor for a first venous thrombosis: a case-control study. Blood 115, 4344-4349 (2010
200. Severinsen, M. T., et al. Risk of venous thromboembolism in patients with primary chronic immune thrombocytopenia: a Danish population-based cohort study. Br. J. Haematol. 152, 360-362 (2011
201. Boyle, S., White, R. H., Brunson, A., & Wun, T. Splenectomy and the incidence of venous thromboembolism and sepsis in patients with immune thrombocytopenia. Blood 121, 4782-4790 (2013
202. Grainge, M. J., West, J., & Card, T. R. Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. Lancet 375, 657-663 (2010
203. Dentali, F., et al. JAK2V617F mutation for the early diagnosis of Ph-myeloproliferative neoplasms in patients with venous thromboembolism: a meta-Analysis. Blood 113, 5617-5623 (2009
204. Barbui, T., et al. Thrombosis in primary myelofibrosis: incidence and risk factors. Blood 115, 778-782 (2010
205. Folsom, A. R., et al. Chronic kidney disease and venous thromboembolism: a prospective study. Nephrol. Dial. Transplant. 25, 3296-3301 (2010
206. Kayali, F., Najjar, R., Aswad, F., Matta, F., & Stein, P. D. Venous thromboembolism in patients hospitalized with nephrotic syndrome. Am. J. Med. 121, 226-230 (2008
207. Brodsky, R. A. Paroxysmal nocturnal hemoglobinuria: stem cells and clonality. Hematology Am. Soc. Hematol. Educ. Program 2008, 111-115 (2008
208. Bacani, A. K., Gabriel, S. E., Crowson, C. S., Heit, J. A., & Matteson, E. L. Noncardiac vascular disease in rheumatoid arthritis: increase in venous thromboembolic events?. Arthritis Rheum. 64, 53-61 (2012
209. Holmqvist, M. E., et al. Risk of venous thromboembolism in patients with rheumatoid arthritis and association with disease duration and hospitalization. JAMA 308, 1350-1356 (2012
210. Arnulf, I., et al. Obstructive sleep apnea and venous thromboembolism. JAMA 287, 2655-2656 (2002
211. Peng, Y. H., et al. Association between obstructive sleep apnea and deep vein thrombosis /pulmonary embolism: a population-based retrospective cohort study. Thromb. Res. 134, 340-345 (2014
212. Austin, H., et al. Sickle cell trait and the risk of venous thromboembolism among blacks. Blood 110, 908-912 (2007
213. Merkel, P. A., et al. Brief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener's Clinical Occurrence of Thrombosis (WeCLOT) Study. Ann. Intern. Med. 142, 620-626 (2005
214. Sanson, B. J., et al. The incidence of venous thromboembolism in asymptomatic carriers of a deficiency of antithrombin, protein C, or protein S: a prospective cohort study. Blood 94, 3702-3706 (1999
215. Folsom, A. R., Cushman, M., Tsai, M. Y., Heckbert, S. R., & Aleksic, N. Prospective study of the G20210A polymorphism in the prothrombin gene, plasma prothrombin concentration, and incidence of venous thromboembolism. Am. J. Hematol. 71, 285-290 (2002
216. Vossen, C. Y., & Rosendaal, F. R. The protective effect of the factor XIII Val34Leu mutation on the risk of deep venous thrombosis is dependent on the fibrinogen level. J. Thromb. Haemost. 3, 1102-1103 (2005
217. Vossen, C. Y., et al. Recurrence rate after a first venous thrombosis in patients with familial thrombophilia. Arterioscler. Thromb. Vasc. Biol. 25, 1992-1997 (2005
218. Bombeli, T., Piccapietra, B., Boersma, J., Fehr, J. Decreased anticoagulant response to tissue factor pathway inhibitor in patients with venous thromboembolism and otherwise no evidence of hereditary or acquired thrombophilia. Thromb. Haemost. 91, 80-86 (2004
219. Broze, G. J. Jr & Miletich, J. P. Human Protein Z. J. Clin. Invest. 73, 933-938 (1984
220. Yin, Z. F., et al. Prothrombotic phenotype of protein Z deficiency. Proc. Natl Acad. Sci. USA 97, 6734-6738 (2000
221. Han, X., Fiehler, R., & Broze, Jr. G.J. Isolation of a protein Z dependent plasma protease inhibitor. Proc. Natl Acad. Sci. USA 95, 9250-9255 (1998
222. Han, X., Huang, Z. F., Fiehler, R., & Broze, Jr. G.J. The protein Z dependent protease inhibitor is a serpin. Biochemistry 38, 11073-11078 (1999
223. Souri, M., Koseki-Kuno, S., Iwata, H., Kemkes-Matthes, B., & Ichinose, A. A naturally occurring E30Q mutation in the Gla domain of protein Z causes its impaired secretion and subsequent deficiency. Blood 105, 3149-3154 (2005
224. Uitte de Willige, S., et al. Genetic variation in the fibrinogen gamma gene increases the risk for deep venous thrombosis by reducing plasma fibrinogen gamma' levels. Blood 106, 4176-4183 (2005
225. Press, R. D., Bauer, K. A., Kujovich, J. L., & Heit, J. A. Clinical utility of factor V leiden (R506Q) testing for the diagnosis and management of thromboembolic disorders. Arch. Pathol. Lab. Med. 126, 1304-1318 (2002
226. Folsom, A. R., et al. A prospective study of venous thromboembolism in relation to factor V Leiden and related factors. Blood 99, 2720-2725 (2002
227. Juul, K., Tybjaerg-Hansen, A., Schnohr, P., & Nordestgaard, B. G. Factor V Leiden and the risk for venous thromboembolism in the adult Danish population. Ann. Intern. Med. 140, 330-337 (2004
228. Chandler, W. L., Rodgers, G. M., Sprouse, J. T., & Thompson, A. R. Elevated hemostatic factor levels as potential risk factors for thrombosis. Arch. Pathol. Lab. Med. 126, 1405-1414 (2002
229. van Hylckama Vlieg, A., & Rosendaal, F. R. High levels of fibrinogen are associated with the risk of deep venous thrombosis mainly in the elderly. J. Thromb. Haemost. 1, 2677-2678 (2003
230. Wells, P. S., Langlois, N. J., Webster, M. A., Jaffey, J., & Anderson, J. A. Elevated factor VIII is a risk factor for idiopathic venous thromboembolism in Canada-is it necessary to define a new upper reference range for factor VIII?. Thromb. Haemost. 93, 842-846 (2005
231. McGlennen, R. C., & Key, N. S. Clinical and laboratory management of the prothrombin G20210A mutation. Arch. Pathol. Lab. Med. 126, 1319-1325 (2002
232. Koster, T., Blann, A. D., Briët, E., Vandenbroucke, J. P., & Rosendaal, F. R. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 345, 152-155 (1995
233. MacCallum, P. K., et al. Clotting factor VIII and risk of deep-vein thrombosis. Lancet 345, 804 (1995
234. Kraaijenhagen, R. A., et al. High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism. Thromb. Haemost. 83, 5-9 (2000
235. Bank, I., et al. Elevated levels of FVIII:C within families are associated with an increased risk for venous and arterial thrombosis. J. Thromb. Haemost. 3, 79-84 (2005
236. van Hylckama Vlieg, A., van der Linden, I. K., Bertina, R. M., & Rosendaal, F. R. High levels of factor IX increase the risk of venous thrombosis. Blood 95, 3678-3682 (2000
237. Meijers, J. C., Tekelenburg, W. L., Bouma, B. N., Bertina, R. M., & Rosendaal, F. R. High levels of coagulation factor XI as a risk factor for venous thrombosis. N. Engl. J. Med. 342, 696-701 (2000
238. Ohira, T., et al. ABO blood group, other risk factors and incidence of venous thromboembolism: the Longitudinal Investigation of Thromboembolism Etiology (LITE). J. Thromb. Haemost. 5, 1455-1461 (2007
239. Cushman, M., O'Meara, E. S., Folsom, A. R., & Heckbert, S. R. Coagulation factors IX through XIII and the risk of future venous thrombosis: the Longitudinal Investigation of Thromboembolism Etiology. Blood 114, 2878-2883 (2009
240. Smith, N. L., et al. Novel associations of multiple genetic loci with plasma levels of factor VII, factor VIII, and von Willebrand factor: the CHARGE (Cohorts for Heart and Aging Research in Genome Epidemiology) Consortium. Circulation 121, 1382-1392 (2010
241. Trégouët, D. A., et al. Common susceptibility alleles are unlikely to contribute as strongly as the FV and ABO loci to VTE risk: results from a GWAS approach. Blood 113, 5298-5303 (2009
242. de Haan, H. G., et al. Multiple SNP testing improves risk prediction of first venous thrombosis. Blood 120, 656-663 (2012
243. Cohen, W., et al. ABO blood group and von Willebrand factor levels partially explained the incomplete penetrance of congenital thrombophilia. Arterioscler. Thromb. Vasc. Biol. 32, 2021-2028 (2012
244. Heit, J. A., et al. A genome-wide association study of venous thromboembolism identifies risk variants in chromosomes 1q24.2 and 9q. J. Thromb. Haemost. 10, 1521-1531 (2012
245. Tang, W., et al. A genome-wide association study for venous thromboembolism: the extended cohorts for heart and aging research in genomic epidemiology (CHARGE) consortium. Genet. Epidemiol. 37, 512-521 (2013
246. Tripodi, A., Chantarangkul, V., Martinelli, I., Bucciarelli, P., & Mannucci, P. M. A shortened activated partial thromboplastin time is associated with the risk of venous thromboembolism. Blood 104, 3631-3634 (2004
247. Folsom, A. R., Cushman, M., Heckbert, S. R., Rosamond, W. D., & Aleksic, N. Prospective study of fibrinolytic markers and venous thromboembolism. J. Clin. Epidemiol. 56, 598-603 (2003
248. Lisman, T., de Groot, P. G., Meijers, J. C., & Rosendaal, F. R. Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis. Blood 105, 1102-1105 (2005
249. André, P., Hartwell, D., Hrachovinová, I., Saffaripour, S., & Wagner, D. D. Pro-coagulant state resulting from high levels of soluble P selectin in blood. Proc. Natl Acad. Sci. USA 97, 13835-13840 (2000
250. Reitsma, P. H., & Rosendaal, F. R. Activation of innate immunity in patients with venous thrombosis: the Leiden Thrombophilia Study. J. Thromb. Haemost. 2, 619-622 (2004
251. Souto, J. C., et al. Genetic determinants of hemostasis phenotypes in Spanish families. Circulation 101, 1546-1551 (2000
252. de Lange, M., Snieder, H., Ariëns, R. A., Spector, T. D., & Grant, P. J. The genetics of haemostasis: a twin study. Lancet 357, 101-105 (2001
253. Vossen, C. Y., et al. Heritability of plasma concentrations of clotting factors and measures of a prethrombotic state in a protein C deficient family. J. Thromb. Haemost. 2, 242-247 (2004
254. Morange, P. E., et al. Biological and genetic factors influencing plasma factor VIII levels in a healthy family population: results from the Stanislas cohort. Br. J. Haematol. 128, 91-99 (2005
255. Morange, P. E., & Trégouët, D. A. Current knowledge on the genetics of incident venous thrombosis. J. Thromb. Haemost. 11 (Suppl. 1), 111-121 (2013
256. Oren, E., Smith, N. L., Doggen, C. J., Heckbert, S. R., & Lemaitre, R. N. Body mass index and the risk of venous thrombosis among postmenopausal women. J. Thromb. Haemost. 4, 2273-2275 (2006
257. Severinsen, M. T., et al. Genetic susceptibility, smoking, obesity and risk of venous thromboembolism. Br. J. Haematol. 149, 273-279 (2010
258. Vandenbroucke, J. P., et al. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 344, 1453-1457 (1994
259. Wu, O., et al. Oral contraceptives, hormone replacement therapy, thrombophilias and risk of venous thromboembolism: a systematic review. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study. Thromb. Haemost. 94, 17-25 (2005
260. Pomp, E. R., le Cessie, S., Rosendaal, F. R., & Doggen, C. J. Risk of venous thrombosis: obesity and its joint effect with oral contraceptive use and prothrombotic mutations. Br. J. Haematol. 139, 289-296 (2007
261. van Hylckama Vlieg, A., & Rosendaal, F. R. Interaction between oral contraceptive use and coagulation factor levels in deep venous thrombosis. J. Thromb. Haemost. 1, 2186-2190 (2003
262. van Vlijmen, E. F., et al. Thrombotic risk during oral contraceptive use and pregnancy in women with factor V Leiden or prothrombin mutation: a rational approach to contraception. Blood 118, 2055-2061 (2011
263. Martinelli, I., et al. Inherited thrombophilia and first venous thromboembolism during pregnancy and puerperium. Thromb. Haemost. 87, 791-795 (2002
264. Herrington, D. M., et al. Factor V Leiden, hormone replacement therapy, and risk of venous thromboembolic events in women with coronary disease. Arterioscler. Thromb. Vasc. Biol. 22, 1012-1017 (2002
265. Rosendaal, F. R., et al. Hormonal replacement therapy, prothrombotic mutations and the risk of venous thrombosis. Br. J. Haematol. 116, 851-854 (2002
266. Cushman, M., et al. Estrogen plus progestin and risk of venous thrombosis. JAMA 292, 1573-1580 (2004
267. van Stralen, K. J., Rosendaal, F. R., & Doggen, C. J. Minor injuries as a risk factor for venous thrombosis. Arch. Intern. Med. 168, 21-26 (2008
268. Lindahl, T. L., Lundahl, T. H., Nilsson, L., & Andersson, C. A. APC-resistance is a risk factor for postoperative thromboembolism in elective replacement of the hip or knee-A prospective study. Thromb. Haemost. 81, 18-21 (1999
269. Salvati, E. A., et al. The John Charnley Award: heritable thrombophilia and development of thromboembolic disease after total hip arthroplasty. Clin. Orthop. Relat. Res. 441, 40-55 (2005
270. Blom, J. W., Doggen, C. J., Osanto, S., & Rosendaal, F. R. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 293, 715-722 (2005
271. Libourel, E. J., et al. Co-segregation of thrombophilic disorders in factor V Leiden carriers; the contributions of factor VIII, factor XI, thrombin activatable fibrinolysis inhibitor andlipoprotein(a) to the absolute risk of venous thromboembolism. Haematologica 87, 1068-1073 (2002